Surrozen (SRZN) said Monday it plans to raise up to $175 million in gross proceeds in a private placement with two tranches to fund multiple ophthalmology programs.
In the initial funding tranche, expected to close on Wednesday, the company said it will raise about $70 million by issuing about 6.03 million units, with each unit consisting of one share, or pre-funded warrant, and one half of a common stock warrant, at a purchase price of $11.60.
At the second closing, investors have committed to purchase an additional 9.05 million units, each consisting of one share, or pre-funded warrant, and one half of a common stock warrant at a price of $11.60 for gross proceeds of about $105 million. The second closing is subject Food and Drug Administration clearance of the company's new drug application for SZN-8141, expected in 2026.
Surrozen said it plans to focus its Wnt signal modulation antibody technologies and expertise on ophthalmology applications, including the development of new treatment options for retinopathies. The company also will discontinue development of its SZN-043 drug candidate to treat severe alcohol associated hepatitis, it said Monday
Surrozen recently were down about 4.1% in recent trading.
Price: 11.90, Change: -0.55, Percent Change: -4.42
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.